Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study

Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab comb...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Almulla
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
immunogenicity
IBD
infliximab
azathioprine
vaccine
BNT162b2
Medicine
R
Acceso en línea:https://doaj.org/article/6f581808a6e84b749718e82f308ceecb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares